Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
IMG-007 · 2 trials · 4 indications
To evaluate adverse events (AEs) emergent from multiple doses of IMG-007 in adult participants with AA.
| Arm | Type | Description |
|---|---|---|
| IMG-007 dose 1 | EXPERIMENTAL | Subcutaneous injection as per protocol. |
| IMG-007 dose 2 | EXPERIMENTAL | Subcutaneous injection as per protocol. |
| IMG-007 dose 3 | EXPERIMENTAL | Subcutaneous injection as per protocol. |
| Placebo Crossover | PLACEBO_COMPARATOR | Subcutaneous placebo injection as per protocol. At crossover, IMG-007 subcutaneous injection as per protocol. |
| IMG-007 Dose 1 (300 mg) | EXPERIMENTAL | IMG-007 Dose 1 (300 mg) will be administered intravenously 3 times over 4 weeks |
| IMG-007 Dose 2 (600 mg) | EXPERIMENTAL | IMG-007 Dose 2 (600 mg) will be administered intravenously 3 times over 4 weeks |
| Name | Type | Description |
|---|---|---|
| IMG-007 | DRUG | Participants will receive IMG-007 subcutaneously. |
| Placebo | DRUG | Participants will receive a placebo subcutaneously. |
Key Inclusion Criteria: * Moderate-to-severe AD * Documented history of inadequate response or lack of tolerability to a stable regimen of one or more topical treatment before the Screening visit, or for whom topical treatments are otherwise inadvisable * Female participants who are not pregnant or...
Top 20 of 25 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Eli Lilly and Company | LLY | 6 | PHASE3 | Baricitinib, corticosteroid |
| AbbVie, Inc. | ABBV | 10 | PHASE3 | Upadacitinib, corticosteroids |
| Pfizer Inc. | PFE | 12 | PHASE3 | Abrocitinib |
| Sanofi SA Sponsored ADR | SNY | 13 | PHASE3 | Amlitelimab |
| Regeneron Pharmaceuticals, Inc. | REGN | 4 | PHASE3 | Dupilumab |
| Incyte Corporation | INCY | 3 | PHASE3 | Ruxolitinib, Vehicle |
| Organon & Co. | OGN | 1 | PHASE3 | Tapinarof , 1%, Vehicle |
| Apogee Therapeutics, Inc. | APGE | 3 | PHASE2 | APG777 |
| Novartis AG Sponsored ADR | NVS | 2 | PHASE2 | GIA632 |
| Johnson & Johnson | JNJ | 1 | PHASE2 | JNJ-95597528 |
| Kymera Therapeutics, Inc. | KYMR | 1 | PHASE2 | KT-621 |
| Corvus Pharmaceuticals, Inc. | CRVS | 1 | PHASE2 | Soquelitinib |
| Nektar Therapeutics | NKTR | 1 | PHASE2 | Rezpegaldesleukin |
| Celldex Therapeutics, Inc. | CLDX | 1 | PHASE2 | Barzolvolimab |
| Evommune, Inc. | EVMN | 1 | PHASE2 | EVO756 |
| Sunshine Biopharma Incorporated | SBFM | 3 | PHASE3 | 611, corticosteroid |
| Aclaris Therapeutics, Inc. | ACRS | 1 | PHASE2 | ATI-045 |
| Q32 Bio Inc | QTTB | 1 | PHASE2 | ADX-914 |
| Turn Therapeutics Inc. | TTRX | 1 | PHASE2 | GX-03 |
| Arcutis Biotherapeutics Inc | ARQT | 1 | PHASE1 | ARQ-234 |
IMG-007 is an investigational small molecule being developed for the treatment of atopic dermatitis and alopecia areata (AA). It is currently in clinical development for moderate-to-severe atopic dermatitis and has completed a Phase 1 study in adult alopecia areata participants.
IMG-007 targets OX40, a receptor involved in immune responses. By targeting OX40, IMG-007 aims to modulate immune activity relevant to inflammatory and autoimmune conditions such as atopic dermatitis and alopecia areata.
IMG-007 is being developed by ImageneBio, Inc., a biopharmaceutical company. The company's ticker symbol is IMA.
IMG-007 is in Phase 2 clinical development for moderate-to-severe atopic dermatitis, with a Phase 2 trial currently recruiting participants. A Phase 1 study in alopecia areata has been completed. IMG-007 is investigational and not yet approved by regulatory authorities.
IMG-007 is being studied in two clinical trials. NCT06060977 is a completed Phase 1 study in adult alopecia areata participants. NCT07037901 is a Phase 2 trial currently recruiting participants with moderate-to-severe atopic dermatitis.
No alternative names for IMG-007 have been disclosed. It is identified solely as IMG-007 in clinical trial records and by its developer, ImageneBio, Inc.